OHSU in the news

OHSU sees increase in COVID-19 testing at Portland Expo Center site

MSN January 05, 2022
Oregon Health & Science University's COVID-19 testing site at the Portland Expo Center has been open since March 2020. OHSU started testing at the beginning of the pandemic, and they haven't stop since day one. "We thought we would do the spring, maybe into summer do a few months and we’d be done," said Debbie Lamberger, who runs the drive-thru clinic which is now six lanes wide. "Right now, the demand is as high as we've ever seen it. Much like we saw at the peak of Delta.

OHSU sees increase in COVID-19 testing at Portland Expo Center site

KPTV January 05, 2022
In an interview with KPTV regarding increased demand for testing, Debbie Lamberger says: "We thought we would do the spring, maybe into summer do a few months and we’d be done. Right now, the demand is as high as we've ever seen it. Much like we saw at the peak of delta."

Will omicron overwhelm Oregon’s hospitals? Here’s what we know so far

OPB's Think Out Loud January 05, 2022
With Oregon Health & Science University’s statewide forecast predicting that the total number of hospitalized COVID-19 patients could soon exceed the delta wave peak, hospitals are yet again revisiting their surge capacity plans and OHA is preparing to roll out new crisis standards of care.

OHSU pediatrician recommends students wear surgical grade masks

KPTV January 04, 2022
Eliza Hayes Bakken, M.D., tells KPTV the omicron-variant is more transmissible than other variants, specifically through airborne spread, and an extra layer of filtration from the K-N95 masks may improve statewide efforts in reducing its spread: “So, the surgical masks, the K-N95 or the K-F-94s coming from other countries and meant to be medical masks – they are built to have more filtration in them. The cloth, a weave of fabric, is going to be looser than the weave of a filter of a surgical grade mask. Those little particles that are airborne can still get through the cloth mask and be spread.”

FDA OKs endogenous Cushing's syndrome treatment

MedPage Today January 04, 2022
OHSU's Maria Fleseriu, M.D., speaks with Medpage Today about the FDA approval of Levoketoconazole (Recorlev) to treat Cushing's syndrome. Fleseriu says: "In prospective clinical studies, treatment with levoketoconazole was shown to be effective for reducing and normalizing cortisol."
See more stories